Page 55 - ARNM-2-4

Advances in Radiotherapy
& Nuclear Medicine Efficacy of stereotactic radiotherapy

response (CR), partial response (PR), stable disease (SD), Table 1. Patient characteristics
or progressive disease (PD). The objective response rate
(ORR) was calculated as CR + PR divided by the total Characteristic Total (n = 96)
number of patients. The disease control rate (DCR) was Sex
calculated as CR + PR + SD divided by the total number Male 70 (72.92%)
of patients. Female 26 (27.08%)
Progression-free survival (PFS) was defined as the time Age (years)
from SRT to disease progression or death, whereas OS was ≤60 61 (63.54%)
defined as the duration from the initiation of SRT to death >60 35 (36.46%)
from any cause. ECOG PS
2.4. Endpoints and statistical analysis 0 42 (43.75%)
1 40 (41.67%)
The primary endpoints of the study were tumor response,
OS, and PFS. The secondary endpoint was acute toxicity, 2 14 (14.58%)
which was defined as adverse events occurring from the Oligometastases (SRT for organ)
beginning of SRT to 3 months after treatment. Acute Liver 38 (39.58%)
toxicity was assessed based on the Common Terminology Lung 23 (23.96%)
Criteria for Adverse Events version 5.0. Brain 35 (36.46%)
All statistical analyses were performed using IBM SPSS Primary tumor
Statistics for Windows, version 27.0 (IBM Corp., Armonk, Lung 46 (47.92%)
NY, USA). Patient characteristics and 3-month treatment Liver 31 (32.29%)
outcomes were reported as frequencies and percentages. Alimentary tract 7 (7.29%)
Tumor response comparisons were conducted using the Others 12 (12.50%)
Ward algorithm in a single-sample proportional test.
Tumor histology
3. Results Hepatocellular carcinoma 31 (32.29%)
3.1. Patient characteristics Adenocarcinoma 44 (45.83%)
Squamous cell carcinoma 7 (7.29%)
This study included 96 patients with a median age of 56
(range, 18 – 83) years, comprising 70 men (72.92%) and 26 Others 14 (14.59%)
women (27.08%). The distribution of oligometastases was Primary tumor surgery
as follows: lung, 23 (23.96%) patients; liver, 38 (39.58%) Yes 38 (39.58%)
patients; and brain, 35 (36.46%) patients. PS scores were No 58 (60.42%)
0, 1, and 2 in 42 (43.75%), 40 (41.67%), and 14 (14.58%) Chemotherapy
patients, respectively. In terms of the treatment methods, Yes 51 (53.13%)
38 (39.58%) patients underwent surgical resection of No 45 (46.87%)
the primary tumor before receiving SRT. Concurrent
chemotherapy was administered to 51 (53.13%) patients, Immunotherapy
whereas combined targeted therapy was administered to Yes 35 (36.46%)
55 (57.29%) patients. Immunotherapy was administered to No 61 (63.54%)
35 (36.46%) patients. The median radiotherapy dose was Targeted therapy
50 Gy (range, 24 – 60 Gy), with a median of 10 (range, Yes 55 (57.29%)
4 – 12) sessions. Using an α/β value of 10, the median No 41 (42.71%)
biological effective dose was 75 Gy (range, 39 – 100 Gy; Abbreviations: ECOG PS: Eastern Cooperative Oncology Group
Table 1). performance status; SRT: Stereotactic radiotherapy.

3.2. Efficacy outcomes
All patients survived for at least 3 months post-treatment. In the subgroup with liver oligometastases (n = 38),
Among them, 13 (13.54%) achieved CR, 50 (52.08%) 10 (26.32%) patients achieved CR, 19 (50.00%) patients
showed PR, 27 (28.13%) exhibited SD, and 6 (6.25%) had PR, 8 (21.05%) patients exhibited SD, and 1 (2.63%)
experienced PD. The ORR was 65.62%, and the DCR was patient showed PD. The ORR and DCR for this subgroup
93.75% (Figure 1). were 76.32% and 97.37%, respectively. Among those with

Volume 2 Issue 4 (2024) 3 doi: 10.36922/arnm.3391